Gouty Arthritis (Gout) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Gouty Arthritis (Gout) – Pipeline Review, H2 2016’, provides an overview of the Gouty Arthritis (Gout) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout)

The report reviews pipeline therapeutics for Gouty Arthritis (Gout) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Gouty Arthritis (Gout) therapeutics and enlists all their major and minor projects

The report assesses Gouty Arthritis (Gout) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Gouty Arthritis (Gout)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allena Pharmaceuticals, Inc.

AstraZeneca Plc

C&C Research Laboratories

Cell Medica Limited

Immune Response BioPharma, Inc.

IOmet Pharma

Jiangsu Hengrui Medicine Co., Ltd.

LG Life Science LTD.

Monosol Rx LLC

Nimbus Therapeutics, LLC

Opsona Therapeutics Limited

Polaris Pharmaceuticals, Inc.

ProteoThera, Inc.

Selvita S.A.

Swedish Orphan Biovitrum AB

Teijin Pharma Limited

TWi Pharmaceuticals, Inc.

Wellstat Therapeutics Corporation

XL-protein GmbH

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Gouty Arthritis (Gout) Overview 10

Therapeutics Development 11

Pipeline Products for Gouty Arthritis (Gout) - Overview 11

Pipeline Products for Gouty Arthritis (Gout) - Comparative Analysis 12

Gouty Arthritis (Gout) - Therapeutics under Development by Companies 13

Gouty Arthritis (Gout) - Therapeutics under Investigation by Universities/Institutes 15

Gouty Arthritis (Gout) - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Gouty Arthritis (Gout) - Products under Development by Companies 20

Gouty Arthritis (Gout) - Products under Investigation by Universities/Institutes 22

Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development 23

Allena Pharmaceuticals, Inc. 23

AstraZeneca Plc 24

C&C Research Laboratories 25

Cell Medica Limited 26

Immune Response BioPharma, Inc. 27

IOmet Pharma 28

Jiangsu Hengrui Medicine Co., Ltd. 29

LG Life Science LTD. 30

Monosol Rx LLC 31

Nimbus Therapeutics, LLC 32

Opsona Therapeutics Limited 33

Polaris Pharmaceuticals, Inc. 34

ProteoThera, Inc. 35

Selvita S.A. 36

Swedish Orphan Biovitrum AB 37

Teijin Pharma Limited 38

TWi Pharmaceuticals, Inc. 39

Wellstat Therapeutics Corporation 40

XL-protein GmbH 41

Gouty Arthritis (Gout) - Therapeutics Assessment 42

Assessment by Monotherapy Products 42

Assessment by Target 43

Assessment by Mechanism of Action 45

Assessment by Route of Administration 47

Assessment by Molecule Type 49

Drug Profiles 51

ALLN-346 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

anakinra - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

APP-112 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

AQB-565 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

AXIBU-03 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

colchicine - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

diacerein - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

DLX-2323 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

DLX-2681 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

febuxostat - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

IR-888 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

LC-350189 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation and Respiratory Infections - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

ND-2110 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

ND-2158 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

ND-346 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

pegadricase - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

PRT-1000 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Recombinant Enzyme for Gout and Tumor Lysis Syndrome - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

REV-002 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

RLBN-1001 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

SEL-212 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

SHR-4640 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Small Molecule Inflammasome Modulator Programme - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Small Molecules to Inhibit GLUT9 for Gout - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

TMX-049 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

URC-102 - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

uriSHELS - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

verinurad - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

WT-2107 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

XEN-102 - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

XEN-104 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

XL-400 - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

Gouty Arthritis (Gout) - Dormant Projects 90

Gouty Arthritis (Gout) - Discontinued Products 93

Gouty Arthritis (Gout) - Product Development Milestones 94

Featured News & Press Releases 94

Oct 26, 2016: Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout 94

Jun 27, 2016: TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment 95

May 10, 2016: Revive Therapeutics Provides Clinical and Corporate Update 95

Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra) 96

Mar 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra) 96

Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients 97

Dec 23, 2015: Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout 98

Oct 19, 2015: MonoSol Rx Leadership Presents Data Supporting PharmFilm Technology Effective for Oral Peptide Delivery 99

Sep 30, 2015: Revive Therapeutics Announces Positive Interim Results From Phase 2a Study of REV-002 in the Treatment of Acute Gout Flares 99

Jun 30, 2015: New Indication for Teijin Pharma’s Febuxostat in Europe 100

Jun 10, 2015: Selecta Biosciences Initiates Phase 1 Clinical Program of SEL-212, Designed As the First Non-Immunogenic Biologic Treatment for Gout 101

Feb 27, 2015: Stiris Research Awarded a Phase IIa Trial in Gout 101

Feb 26, 2015: Revive Therapeutics Expands its Orphan Drug Indication Pipeline to Include Cystinuria and Wilson Disease 101

Dec 12, 2014: TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan 102

Nov 26, 2014: Revive Therapeutics Announces US FDA Acceptance of IND to Commence Clinical Trial for Bucillamine for the Treatment of Gout 102

Appendix 104

Methodology 104

Coverage 104

Secondary Research 104

Primary Research 104

Expert Panel Validation 104

Contact Us 104

Disclaimer 105

List of Tables

List of Tables

Number of Products under Development for Gouty Arthritis (Gout), H2 2016 11

Number of Products under Development for Gouty Arthritis (Gout) – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Development by Companies, H2 2016 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Development, H2 2016 18

Comparative Analysis by Unknown Stage Development, H2 2016 19

Products under Development by Companies, H2 2016 20

Products under Development by Companies, H2 2016 (Contd..1) 21

Products under Investigation by Universities/Institutes, H2 2016 22

Gouty Arthritis (Gout) – Pipeline by Allena Pharmaceuticals, Inc., H2 2016 23

Gouty Arthritis (Gout) – Pipeline by AstraZeneca Plc, H2 2016 24

Gouty Arthritis (Gout) – Pipeline by C&C Research Laboratories, H2 2016 25

Gouty Arthritis (Gout) – Pipeline by Cell Medica Limited, H2 2016 26

Gouty Arthritis (Gout) – Pipeline by Immune Response BioPharma, Inc., H2 2016 27

Gouty Arthritis (Gout) – Pipeline by IOmet Pharma, H2 2016 28

Gouty Arthritis (Gout) – Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 29

Gouty Arthritis (Gout) – Pipeline by LG Life Science LTD., H2 2016 30

Gouty Arthritis (Gout) – Pipeline by Monosol Rx LLC, H2 2016 31

Gouty Arthritis (Gout) – Pipeline by Nimbus Therapeutics, LLC, H2 2016 32

Gouty Arthritis (Gout) – Pipeline by Opsona Therapeutics Limited, H2 2016 33

Gouty Arthritis (Gout) – Pipeline by Polaris Pharmaceuticals, Inc., H2 2016 34

Gouty Arthritis (Gout) – Pipeline by ProteoThera, Inc., H2 2016 35

Gouty Arthritis (Gout) – Pipeline by Selvita S.A., H2 2016 36

Gouty Arthritis (Gout) – Pipeline by Swedish Orphan Biovitrum AB, H2 2016 37

Gouty Arthritis (Gout) – Pipeline by Teijin Pharma Limited, H2 2016 38

Gouty Arthritis (Gout) – Pipeline by TWi Pharmaceuticals, Inc., H2 2016 39

Gouty Arthritis (Gout) – Pipeline by Wellstat Therapeutics Corporation, H2 2016 40

Gouty Arthritis (Gout) – Pipeline by XL-protein GmbH, H2 2016 41

Assessment by Monotherapy Products, H2 2016 42

Number of Products by Stage and Target, H2 2016 44

Number of Products by Stage and Mechanism of Action, H2 2016 46

Number of Products by Stage and Route of Administration, H2 2016 48

Number of Products by Stage and Molecule Type, H2 2016 50

Gouty Arthritis (Gout) – Dormant Projects, H2 2016 90

Gouty Arthritis (Gout) – Dormant Projects (Contd..1), H2 2016 91

Gouty Arthritis (Gout) – Dormant Projects (Contd..2), H2 2016 92

Gouty Arthritis (Gout) – Discontinued Products, H2 2016 93

List of Figures

List of Figures

Number of Products under Development for Gouty Arthritis (Gout), H2 2016 11

Number of Products under Development for Gouty Arthritis (Gout) – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Products, H2 2016 18

Assessment by Monotherapy Products, H2 2016 42

Number of Products by Top 10 Targets, H2 2016 43

Number of Products by Stage and Top 10 Targets, H2 2016 43

Number of Products by Top 10 Mechanism of Actions, H2 2016 45

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 45

Number of Products by Routes of Administration, H2 2016 47

Number of Products by Stage and Routes of Administration, H2 2016 47

Number of Products by Molecule Types, H2 2016 49

Number of Products by Stage and Molecule Types, H2 2016 49

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports